Company intelligence / Profile preview

Enlivex Therapeutics

Ness Ziona / Nes-Ziona / Ness-Ziona, Israelenlivex.com ↗

Ownership: Public · ENLV
Development stage: Other

Overview

Enlivex has demonstrated a favorable safety profile for Allocetra™, with over 150 patients treated in clinical trials and no reported drug-related serious adverse events. Interim data from the Phase I stage of the moderate-to-severe knee osteoarthritis trial showed statistically significant improvements in efficacy endpoints without safety concerns. The ongoing randomized, placebo-controlled Phase II trial has completed enrollment and topline three-month data are expected by August 2025[2][6][7][9].

Therapeutic areas: Infectious DiseasesRheumatology
Modalities: Cell therapy (off-the-shelf)Macrophage reprogramming immunotherapy
Industry: Biotech

Drug pipeline

3 assets

Allocetra

2 more assets in the full pipeline.

Financials

Market cap: $21.4M
Total revenue: $0
Enterprise value: $33.1M

Beyond the preview

Go deeper on Enlivex Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enlivex Therapeutics.